Genetic mechanisms of electroconvulsive therapy response in depression

Electroconvulsive therapy (ECT) is known to be one of the most effective treatments for managing depression and other severe mental illnesses. Nevertheless, the exact mechanisms underlying response to ECT remain uncertain. This mini‐review presents clinical findings regarding the role of genetic factors in the aetiology of the ECT response. Studies on the role of variation in the catechol‐O‐methyltransferase (COMT) gene; other dopamine‐, serotonin‐, and G‐protein‐related genes; brain‐derived neurotrophic factor (BDNF); apolipoprotein E (APOE); angiotensin I‐converting enzyme (ACE) and vascular endothelial growth factor (VEGF) genes in mediating response to ECT are summarized. The existing data support the notion that some genetic factors—particularly the functional COMT val158met polymorphism—may play a role in the magnitude of clinical response to ECT, and thus could serve as potential biomarkers for future personalized treatment approaches. However, much of the work to date is preliminary, and large‐scale confirmatory studies are still needed. Copyright © 2016 John Wiley & Sons, Ltd.

Source: Human Psychopharmacology: Clinical and Experimental - April 5, 2016 Category: Psychiatry Authors: Janine J. Benson‐Martin, Dan J. Stein, David S. Baldwin, Katharina Domschke Tags: Short Communication Source Type: research